MAIA Biotechnology, Inc.MAIAEarnings & Financial Report
NYSE · Health Care · Pharmaceutical Preparations
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical firm developing innovative targeted therapies for hard-to-treat adult cancers. Its lead pipeline candidates target specific oncogenic pathways, operating primarily in North America's oncology market to address unmet medical needs for patients with limited treatment options.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Vlad Vitoc | 13.29% | 3.5M | — | 2024-10-25 |
| Louie Ngar Yee | 6.50% | 1.6M | — | 2024-10-25 |
| The Stan V. Smith Trust Dated 1993 | 6.32% | 1.5M | — | 2024-10-25 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
No transactions match these filters.